Ligand id: 9429

Name: miransertib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 95.64
Molecular weight 432.21
XLogP 6.62
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
ARQ-092 has reached Phase 1/1b development in solid and liquid tumours (click here to link to ClinicalTrials.gov's full list of ARQ-092 trials). ARQ-092 is also being evaluated for its potential to inhibit somatic over-growth in patients with Proteus syndrome [2], which is reported to be driven by mosaicism for the E17K activating AKT1 mutation.